A Randomized, Partially-Blinded, Multi-Center, Active-Controlled, Dose-Ranging Study Assessing the Safety, Efficacy, and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects With Acute Coronary Syndrome.

Trial Profile

A Randomized, Partially-Blinded, Multi-Center, Active-Controlled, Dose-Ranging Study Assessing the Safety, Efficacy, and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects With Acute Coronary Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Anivamersen-pegnivacogin (Primary) ; Heparin; Low molecular weight heparins
  • Indications Acute coronary syndromes
  • Focus Therapeutic Use
  • Acronyms RADAR
  • Sponsors Regado Biosciences
  • Most Recent Events

    • 05 Dec 2012 A summary of the results of the RADAR study will be presented at the Oppenheimer 23rd Annual Healthcare Conference, according to a Regado Biosciences media release, as well as a summary of the results of the FDA end-of-phase 2 meeting.
    • 02 Aug 2012 Results published in the European Heart Journal.
    • 14 Mar 2012 Results will be presented at the BIO-Europe Spring 2012 conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top